trending Market Intelligence /marketintelligence/en/news-insights/trending/lb8tWCMUdK9X-2WKRwOnGA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Mitsubishi Tanabe completes acquisition of NeuroDerm

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Mitsubishi Tanabe completes acquisition of NeuroDerm

Mitsubishi Tanabe Pharma Corp. completed the $1.12 billion acquisition of Israel-based pharmaceutical company NeuroDerm Ltd.

Under the deal, a unit of Mitsubishi Tanabe was merged with and into NeuroDerm, with the latter being the surviving corporation and a wholly owned subsidiary of the Japanese pharmaceutical company.

NeuroDerm's shareholders were entitled to receive $39 in cash per share. NeuroDerm's ordinary shares will cease to trade on the Nasdaq global market.